

Final Office Action issued on March 21, 2002. Applicants would like to note that claim 7 has also been amended to depend from claim 18 (previously claim 22) as the claims have been renumbered. No new matter has been added.

Applicants are also filing an Information Disclosure Statement in order to complete the record. Applicants submit that the claims are in condition for allowance.

CONCLUSION


The Applicants respectfully request entry of the foregoing amendment and remarks into the file of the above-identified application.

It is believed that no fee is due in connection with this amendment. In the event that the Patent Office believes that a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

If any outstanding issues remain, the Examiner is invited to telephone the undersigned to discuss the same and to arrange for prompt and efficient handling of the above-identified application.

Respectfully submitted,

Date November 6, 2002



Anthony M. Insogna (Reg. No. 35,203)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

EXHIBIT A
MARKED VERSION OF THE CLAIMS
U.S. PATENT APPLICATION SERIAL NO. 09/674,877
(Deleted text is bracketed, added text is underlined)

7. (Twice amended) Epothilone derivative as in claims 4, 5, 6 or [22] 18
wherein the substituents of the monocyclic aromatic and/or hetero aromatic are C₁₋₆-alkyl, C₂₋₆-alkenyl, and C₂₋₆-alkinyl groups respectively [[, especially C₁₋₄-alkyl, C₂₋₄-alkenyl, and C₂₋₄-alkinyl groups, respectively]], and fluoro, chloro, bromo or iodo atoms.